Further evidence for favorable cost-effectiveness of elderly influenza vaccinationMultiple chronic conditions and healthcare costs among adultsEstimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxisAutism spectrum disorders: a review of measures for clinical, health services and cost-effectiveness applicationsTrends in translation requests and arising issues regarding cultural adaptationThe reliability and validity of the Iranian version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: the EORTC QLQ-BM22Analysis of the implementation of a personalized care model in diabetes mellitus as an example of chronic disease with information and communication technology supportCost-effective approaches to influenza prevention and treatment.Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications.The unknown burden and cost of celiac disease in the U.S.Direct and indirect cost of managing alzheimer's disease and related dementias in the United States.Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications.Healthcare burden of depression in adults with arthritis.Validation and calibration of structural models that combine information from multiple sources.Productivity losses associated with cardiovascular disease: a systematic review.Cost-effectiveness of professional pharmacy services in community pharmacy: a systematic review.How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: a five-step approach (part 1/3).How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3).Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry.Cognitive dysfunction and work productivity in major depressive disorder.Risk of bias in model-based economic evaluations: the ECOBIAS checklist.Condom effectiveness in reducing heterosexual HIV transmission: a systematic review and meta-analysis of studies on HIV serodiscordant couples.Adoption of ipilimumab in the United States: a Medicare study.Cost-effectiveness of managing HIV infection.Mitigation of pandemic influenza: review of cost-effectiveness studies.Is oseltamivir (Tamiflu) safe? Re-examining the Tamiflu 'ado' from Japan.Is there an alternative to quality-adjusted life years for supporting healthcare decision making?Recommendations for the prevention and treatment of influenza using antiviral drugs based on cost-effectiveness.Palliative care for surgical patients.The impact of chronic conditions on the economic burden of cancer survivorship: a systematic reviewEconomic and care considerations of Marfan syndrome.Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.How to prepare a systematic review of economic evaluations for clinical practice guidelines: database selection and search strategy development (part 2/3).Robotic surgery in urologic oncology: gathering the evidence.Reporting bias and other biases affecting systematic reviews and meta-analyses: a methodological commentary.The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.Application of electronic medical record data for health outcomes research: a review of recent literature.Costs of multiple sclerosis - extrapolation of Czech data to Polish patients.Generating appropriate clinical data for value assessment of medical devices: what role does regulation play?Can administrative data be used to measure chemotherapy side effects?
P1433
Q22305948-2CDDC676-876F-4BCF-BBBE-81965196BA3DQ26781767-4C135C92-6C39-4220-8930-519C2DB82410Q26865814-38A5EE56-823B-49E3-94E2-3941877166ECQ27004613-AF9B2C42-C449-490E-B9E3-4A859BB79A0DQ28240637-39E9B3FB-0937-4B9B-A516-4D44B64069C5Q28303771-101EC16B-C13C-4FE8-8EDF-F7B80E6FAABBQ29994601-8E301BE2-9607-41A9-926A-7C33DEBEA123Q30233084-682AA651-0C24-4F4A-906C-1DBED56E020AQ30234836-F65038DD-07E1-4A9A-A127-CA5A5B48C2ACQ30234960-ED59E239-58B3-4203-AEB8-FBEF81B3EDB7Q30235057-1A810A64-6A78-40CE-B41B-A1F96ABB2456Q30235338-681C4210-00A3-4321-87E0-52B8D24A1EEFQ30238991-C1C3CEB0-EEEA-4ECD-9236-1CCB1A795E15Q30239838-F7576960-B87B-442D-856A-C247655559F2Q30241494-BFDE351F-24BB-49A8-A3EF-A90248802F7AQ30241568-1AE9B101-8008-438F-879F-1D82B9AF2D6AQ30241967-2474B7CC-8BD2-4A4A-8CFF-FE9D00CB4083Q30244313-CB2AC437-3BC6-4A66-8719-2FEF632CA56DQ30245173-6E1F7207-AF8F-4A6C-87DA-5B5286C699A3Q30249792-A46FE903-BAEF-4BD8-B890-5B74E876EBA0Q30252032-53D39DC4-DA8C-4BB2-B5CC-5460A6A38E29Q30252069-F65992BC-955B-479D-A102-8CE93E384674Q30276953-6350B189-6222-44EB-A3FB-07040ADE9E11Q30381397-A8AAF664-3D37-42BF-9584-69B2D42C2D08Q30382889-DD1F6504-D67F-49C6-AD92-AC3849F43A13Q30385163-D09B7CB2-4022-41D1-A04F-E9125C23643EQ30387584-659B356E-2166-460D-A2DC-8181904C0604Q30390080-C00D7169-88F7-4BA0-A191-BD07AF85F83DQ30390083-DD661F7C-C62F-447E-A0C9-C38FBAFDDDD6Q30393166-9B7DE596-97C7-4C81-9685-D8A40DE3124BQ30393311-D70ACA96-8932-4E59-8207-35CD04D831A5Q30393824-E34E4012-22EB-4EA5-AEE2-9831B8FB313DQ30394805-4590E367-6DD2-48C7-B4CC-43C670429E89Q30432095-155A4CDF-BFC4-4A77-9069-9D6BAC50359EQ30484545-2F5172BA-1B62-45AB-904E-730280C30106Q30491107-1DB988FC-55A2-47D3-8F09-58591C74F00CQ30613981-8DF05CEE-2E9B-4A2D-9F72-5DEF6E0E88CAQ30793708-53768465-069C-48CE-A1DE-D30A0EF831BCQ30848074-FC718B71-771A-4B77-9C21-E18B41D019B9Q30877306-FF15AD75-63F1-41D6-9B33-5695FA465619
P1433
description
begutachtete wissenschaftliche Zeitschrift
@de
peer-reviewed scientific journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Informa
@nl
рецензований науковий журнал
@uk
वैज्ञानिक पत्रिका
@hi
name
Expert Review of Pharmacoeconomics & Outcomes Research
@ast
Expert Review of Pharmacoeconomics & Outcomes Research
@da
Expert Review of Pharmacoeconomics & Outcomes Research
@de
Expert Review of Pharmacoeconomics & Outcomes Research
@en
Expert Review of Pharmacoeconomics & Outcomes Research
@es
Expert Review of Pharmacoeconomics & Outcomes Research
@fi
Expert Review of Pharmacoeconomics & Outcomes Research
@fr
Expert Review of Pharmacoeconomics & Outcomes Research
@it
Expert Review of Pharmacoeconomics & Outcomes Research
@nb
Expert Review of Pharmacoeconomics & Outcomes Research
@nl
type
label
Expert Review of Pharmacoeconomics & Outcomes Research
@ast
Expert Review of Pharmacoeconomics & Outcomes Research
@da
Expert Review of Pharmacoeconomics & Outcomes Research
@de
Expert Review of Pharmacoeconomics & Outcomes Research
@en
Expert Review of Pharmacoeconomics & Outcomes Research
@es
Expert Review of Pharmacoeconomics & Outcomes Research
@fi
Expert Review of Pharmacoeconomics & Outcomes Research
@fr
Expert Review of Pharmacoeconomics & Outcomes Research
@it
Expert Review of Pharmacoeconomics & Outcomes Research
@nb
Expert Review of Pharmacoeconomics & Outcomes Research
@nl
prefLabel
Expert Review of Pharmacoeconomics & Outcomes Research
@ast
Expert Review of Pharmacoeconomics & Outcomes Research
@da
Expert Review of Pharmacoeconomics & Outcomes Research
@de
Expert Review of Pharmacoeconomics & Outcomes Research
@en
Expert Review of Pharmacoeconomics & Outcomes Research
@es
Expert Review of Pharmacoeconomics & Outcomes Research
@fi
Expert Review of Pharmacoeconomics & Outcomes Research
@fr
Expert Review of Pharmacoeconomics & Outcomes Research
@it
Expert Review of Pharmacoeconomics & Outcomes Research
@nb
Expert Review of Pharmacoeconomics & Outcomes Research
@nl
P243
P3181
P1055
P1058
P1156
P123
P1277
P1476
Expert Review of Pharmacoeconomics & Outcomes Research
@en
P236
P243
P407
P571
2001-01-01T00:00:00Z